Under construction – not a live service
Sign in

2025-523759-76-01RecruitingPhase 1

A Study to Learn How Different Amounts of the Study Medicine Called PF-08065010 are Tolerated and Act in the Body of Healthy Adults

Source: EU CTIS (euclinicaltrials.eu) · Last updated 10 Sept 2026

Next steps

Status (registry)
Recruiting
Phase (registry)
Phase 1
Study type
Interventional
Enrollment
100 (estimated)
First submitted
26 Feb 2026
Start date
15 Apr 2026
Lead sponsor
Pfizer Inc.
EU CT number
2025-523759-76-01

What you commit to

  • Study type: Interventional · Phase 1
  • Planned participants: 100
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.

AI-kivonat: who the study is looking for

Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial studies how different amounts of the study medicine PF-08065010 are tolerated and act in the body of healthy adults.

Age
18 years or older
Sex
All sexes

Read by machine on 9 Nov 2026.

Sites (1)

Sites in registry order. Save your city in your profile to sort them by distance.

SiteCityCountrySite status
Pfizer Clinical Research UnitBrusselsBelgiumRecruiting

Are you the coordinator? Confirm the details

This page is information, not medical advice. Discuss any trial with your doctor.